Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Investigation Launched: Halper Sadeh LLC is investigating whether the sale of Lisata Therapeutics to Kuva Labs for $4.00 per share in cash, plus two non-tradeable contingent value rights, is fair to shareholders, raising concerns about the adequacy of the offer.
- Shareholder Rights Protection: The investigation focuses on whether Lisata's board violated federal securities laws by failing to secure the best possible deal for shareholders, potentially compromising their interests in the transaction.
- Disclosure Deficiencies: Halper Sadeh highlights that Lisata may not have disclosed all material information necessary for shareholders to adequately assess the merger's value, which could impair their decision-making capabilities.
- Potential Legal Action: Halper Sadeh may seek increased consideration for shareholders, additional disclosures, or other legal remedies to ensure that the rights of Lisata shareholders are adequately protected.
Analyst Views on LSTA
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
